Following an admission to the authors’ centre with severe anaemia, duodenal biopsy confirmed the diagnosis of Whipple’s ...

The apparent benefits at 2 years observed in the nonrandomized ALT-FLOW study pave the way for a sham-controlled trial.

This February, Morris-Simon and her colleagues at Bayer are leveraging Heart Month and Black History Month as an opportunity ...

Sildenafil was effective for reducing diastolic dysfunction and altered ejection fraction among patients with SSc.

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...

Blue Trust Inc. lowered its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) by 18.2% during the fourth quarter, according to its most recent disclosure with the Securities ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...